Author/Authors :
Nikzad, Mirsaeed Department of Inorganic Chemistry, University of Mazandaran, Babolsar, Iran , Jalilian, Amir Reza Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran , Shirvani-Arani, Simindokht Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran , Arabieh, Masood Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran , Shanesazzadeh, Saeed Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran , Golchoobian, Hamid Department of Inorganic Chemistry, University of Mazandaran, Babolsar, Iran
Abstract :
Introduction: In this work, 153Sm-zoledronate (153Sm-ZLD) was studied using computational chemistry methods and prepared
for possible use in bone pain palliation therapy.
Methods: The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state using computational chemistry
methods followed by 153Sm-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in
animals were studied and used for absorbed dose determination in critical organs.
Results: The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state and computational chemistry methods
showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. 153Sm-ZLD complex was prepared with
>99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with >95% binding to
HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs.
Conclusion: The 153Sm-ZLD complex data were compared to 153Sm-EDTMP and 153Sm-BPAMD.
Keywords :
153Sm , Zoledronic acid , Biodistribution , Dosimetry , Bone pain palliation
